Short answer
GYRE THERAPEUTICS, INC. (GYRE) filed an 8-K current report with the SEC on July 16, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Three directors appointed effective August 1, 2026: Yue Xiong, Maxwell Kirkby, and Claire Weston.
GYRE THERAPEUTICS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Three directors appointed effective August 1, 2026: Yue Xiong, Maxwell Kirkby, and Claire Weston
- Kirkby joins Compensation Committee; Weston joins Audit Committee, strengthening board committee coverage
- Kirkby and Weston each receive options for 40,000 shares, vesting monthly over three years
- Xiong receives no additional compensation for board service, limiting incremental director expense
- No disclosed related-party transactions, family relationships, or appointment arrangements
Item 7.01 · Regulation FD Disclosure
- Executive appointments announced, with substantive details contained in Exhibit 99.1
- Leadership changes may affect strategy and execution; investors should review Exhibit 99.1 for appointees and roles
Item EX-99.1 · Exhibit EX-99.1
- Board expands by three directors effective August 1, 2026, adding scientific, clinical, governance, and cross-border expertise
- Chief Scientific Officer Yue Xiong appointed Class I director through 2028 annual meeting, strengthening internal pipeline representation
- Maxwell Kirkby joins Compensation Committee, bringing China, Japan, U.S., and Europe drug-development experience
- Claire Weston joins Audit Committee, adding life-sciences operating and public-company governance experience
- Appointments support Gyre’s global pipeline across fibrosis, cancer, inflammation, and pain, including Cullgen degrader platforms
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other GYRE THERAPEUTICS, INC. 8-K filings
Get the next GYRE 8-K as it lands
Follow GYRE for push alerts, or ask the research agent what this filing means.